IRIS UniCatt

Bianco, Assunta
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.648
EU - Europa 1.569
AS - Asia 1.310
SA - Sud America 304
AF - Africa 29
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 2
Totale 4.868
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.601
SG - Singapore 638
DE - Germania 554
CN - Cina 340
SE - Svezia 295
BR - Brasile 256
IT - Italia 173
FR - Francia 104
GB - Regno Unito 96
UA - Ucraina 87
IE - Irlanda 67
IN - India 59
VN - Vietnam 58
FI - Finlandia 55
ID - Indonesia 49
HK - Hong Kong 39
RU - Federazione Russa 28
TR - Turchia 26
AR - Argentina 25
CA - Canada 24
PL - Polonia 21
AT - Austria 19
BD - Bangladesh 17
BE - Belgio 17
IQ - Iraq 17
KR - Corea 15
CI - Costa d'Avorio 13
NL - Olanda 11
MX - Messico 10
VE - Venezuela 9
IR - Iran 8
JP - Giappone 8
IL - Israele 6
SA - Arabia Saudita 6
ES - Italia 5
DO - Repubblica Dominicana 4
EC - Ecuador 4
JO - Giordania 4
LT - Lituania 4
MA - Marocco 4
RO - Romania 4
SK - Slovacchia (Repubblica Slovacca) 4
ZA - Sudafrica 4
AU - Australia 3
CO - Colombia 3
CZ - Repubblica Ceca 3
HU - Ungheria 3
NO - Norvegia 3
NP - Nepal 3
PK - Pakistan 3
TN - Tunisia 3
UY - Uruguay 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AE - Emirati Arabi Uniti 2
BG - Bulgaria 2
CH - Svizzera 2
EE - Estonia 2
HR - Croazia 2
KE - Kenya 2
LV - Lettonia 2
MK - Macedonia 2
NI - Nicaragua 2
NZ - Nuova Zelanda 2
PA - Panama 2
PS - Palestinian Territory 2
PY - Paraguay 2
TT - Trinidad e Tobago 2
UZ - Uzbekistan 2
AM - Armenia 1
AO - Angola 1
AZ - Azerbaigian 1
BO - Bolivia 1
BS - Bahamas 1
BY - Bielorussia 1
CL - Cile 1
DK - Danimarca 1
EG - Egitto 1
HT - Haiti 1
JM - Giamaica 1
KG - Kirghizistan 1
LB - Libano 1
LK - Sri Lanka 1
MD - Moldavia 1
MU - Mauritius 1
OM - Oman 1
PG - Papua Nuova Guinea 1
PT - Portogallo 1
SY - Repubblica araba siriana 1
TH - Thailandia 1
Totale 4.868
Salva come PNG Salva come JPEG
Città #
Chandler 328
Singapore 328
Ashburn 152
Beijing 78
Ann Arbor 71
Dublin 67
New York 61
San Mateo 59
Jacksonville 57
Nürnberg 51
Hefei 49
Jakarta 48
Los Angeles 48
Milan 42
Hong Kong 39
Boston 30
Munich 30
Nanjing 28
Wilmington 28
Rome 27
Princeton 25
Woodbridge 24
Dearborn 22
São Paulo 21
Moscow 20
Dallas 19
Helsinki 19
Houston 19
Bremen 18
Ho Chi Minh City 18
Marseille 18
Brussels 17
Chicago 17
Hanoi 17
Frankfurt am Main 16
Kent 16
Atlanta 15
Buffalo 15
Nuremberg 15
Pune 15
Seoul 15
Izmir 14
Warsaw 14
Abidjan 13
Turku 13
Norwalk 11
Seattle 11
Brooklyn 10
Cattolica 10
Lawrence 10
London 10
Vienna 10
Redwood City 9
Düsseldorf 8
Lappeenranta 8
Leawood 8
North Bergen 8
Shanghai 8
Boardman 7
Kunming 7
Nanchang 7
Rio de Janeiro 7
Santa Clara 7
Tianjin 7
Amsterdam 6
Andover 6
Ankara 6
Baghdad 6
Denver 6
Detroit 6
Falkenstein 6
Montreal 6
Portsmouth 6
Toronto 6
Belo Horizonte 5
Changsha 5
Dhaka 5
Mountain View 5
Rovato 5
San Francisco 5
Shenyang 5
Stockholm 5
The Dalles 5
Thái Nguyên 5
University Park 5
Amman 4
Bexley 4
Caracas 4
Caxias do Sul 4
Changchun 4
Chennai 4
Edinburgh 4
Erbil 4
Fairfield 4
Fremont 4
Goiânia 4
Guangzhou 4
Haiphong 4
Hebei 4
Jiaxing 4
Totale 2.394
Salva come PNG Salva come JPEG
Nome #
Circulating CD56dim NK cells expressing perforin are increased in progressive multiple sclerosis 247
Second-Line Therapy with Fingolimod for Relapsing-Remitting Multiple Sclerosis in Clinical Practice: The Effect of Previous Exposure to Natalizumab 237
T-bet, pSTAT1 and pSTAT3 expression in peripheral blood mononuclear cells during pregnancy correlates with post-partum activation of multiple sclerosis. 205
CD8(+) T Cells in Facioscapulohumeral Muscular Dystrophy Patients with Inflammatory Features at Muscle MRI 205
The effect of disease activity on leptin, leptin receptor and suppressor of cytokine signalling-3 expression in relapsing-remitting multiple sclerosis. 177
Glucocorticoid treatment reduces T-bet and pSTAT1 expression in mononuclear cells from relapsing remitting multiple sclerosis patients. 159
Lambert-Eaton Myasthenic Syndrome associated with gastric schwannoma 154
Demyelinating Encephalomyeloradiculitis with Balò-like lesions 152
Epstein-Barr virus antibodies in serum and cerebrospinal fluid from Multiple Sclerosis, Chronic Inflammatory Demyelinating Polyradiculoneuropathy and Amyotrophic Lateral 150
Alemtuzumab-induced lung injury in multiple sclerosis: Learning from adversity in three patients 141
Alemtuzumab-induced lung injury in multiple sclerosis: Learning from adversity in three patients 134
Increased CD4(+)CD25(+)Foxp3(+) T Cells in Peripheral Blood of Celiac Disease Patients: Correlation with Dietary Treatment. 133
New onset of Susac syndrome after mRNA COVID-19 vaccine: a case report 113
Epidemiology of intensive care unit-acquired sepsis in Italy: Results of the SPIN-UTI network 112
Dominus effect: challenging complications of alemtuzumab-related thyroid autoimmunity 106
The Expanding Role of the Infectious Disease Expert in the Context of the MS Centre 105
Liposome-based nanoparticles impact on regulatory and effector phenotypes of macrophages and T cells in multiple Sclerosis patients 104
Defining the disease course of TNFα blockers-associated Multiple Sclerosis 104
Glioblastoma in multiple sclerosis: a case report 103
Disease Reactivation after Fingolimod Discontinuation in Pregnant Multiple Sclerosis Patients 97
Severe dyspnoea with alteration of the diffusion capacity of the lung associated with fingolimod treatment 93
The predictive value of CSF multiple assay in multiple sclerosis: A single center experience 93
Prevalence and predictors of bowel dysfunction in a large multiple sclerosis outpatient population: an Italian multicenter study 92
Fingolimod vs dimethyl fumarate in multiple sclerosis 87
CSF CXCL13 and Chitinase 3-like-1 Levels Predict Disease Course in Relapsing Multiple Sclerosis 86
The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review 86
Liver injury after pulsed methylprednisolone therapy in multiple sclerosis patients 84
Liposome-based nanoparticles impact on regulatory and effector phenotypes of macrophages and T cells in multiple Sclerosis patients 81
Cyclophosphamide in highly aggressive Marburg-like multiple sclerosis 81
Neurosarcoidosis presenting as longitudinally extensive myelitis: Diagnostic assessment, differential diagnosis, and therapeutic approach 78
Is serological response to SARS-CoV-2 preserved in MS patients on ocrelizumab treatment? A case report 77
Immunogenicity and safety of mRNA COVID-19 vaccines in people with multiple sclerosis treated with different disease-modifying therapies 76
Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment-naïve patients with multiple sclerosis 75
The influence of physiotherapy intervention on patients with multiple sclerosis–related spasticity treated with nabiximols (THC:CBD oromucosal spray) 74
No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study 74
Acyclovir-related kidney injury during alemtuzumab infusion 72
Sativex® effects on promoter methylation and on CNR1/CNR2 expression in peripheral blood mononuclear cells of progressive multiple sclerosis patients 67
Effectiveness of Ocrelizumab in Primary Progressive Multiple Sclerosis: a Multicenter, Retrospective, Real-world Study (OPPORTUNITY) 64
Multiple Sclerosis Onset before and after COVID-19 Vaccination: Can HLA Haplotype Be Determinant? 62
Moving to fingolimod from natalizumab in multiple sclerosis: the ENIGM is not solved 60
A true isolated cognitive relapse in multiple sclerosis 55
Cardiovascular autonomic individual profile of relapsing-remitting multiple sclerosis patients and risk of extending cardiac monitoring after first dose fingolimod 55
COVID-19 outbreak in Italy: an opportunity to evaluate extended interval dosing of ocrelizumab in MS patients 53
The predictive value of CSF multiple assay in multiple sclerosis: A single center experience 52
Correction to: Prevalence and predictors of bowel dysfunction in a large multiple sclerosis outpatient population: an Italian multicenter study (Journal of Neurology, (2022), 269, 3, (1610-1617), 10.1007/s00415-021-10737-w) 50
Clinically relevant increases in serum neurofilament light chain and glial fibrillary acidic protein in patients with Susac syndrome 49
Ocrelizumab in MS patients with persistence of disease activity after alemtuzumab: A multi-center Italian study 48
Real-World 24-Month Outcomes of Ofatumumab in Relapsing Multiple Sclerosis: Efficacy, Safety, and the Impact of Frailty 43
An early feasibility study for neurological devices: The ARCTRAN study 13
IgE-mediated allergic reactions to ocrelizumab in multiple sclerosis: A retrospective cohort study 12
Totale 4.930
Salva come PNG Salva come JPEG
Categoria #
all - tutte 21.389
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 21.389
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021140 0 0 0 0 0 8 23 10 18 20 56 5
2021/2022391 35 16 19 41 13 11 9 61 23 23 54 86
2022/2023878 91 110 61 139 65 116 43 84 100 10 43 16
2023/2024414 19 94 14 21 18 69 35 14 7 20 44 59
2024/2025833 14 25 63 53 45 33 17 26 140 73 188 156
2025/20261.285 325 67 126 250 495 22 0 0 0 0 0 0
Totale 4.930